Form 4: Alumis Inc. Director Akkaraju Increases Stake Through Multiple Transactions
SEC Form 4 Filing
Director Srinivas Akkaraju reports acquiring additional Alumis Inc. (ALMS) common stock through transactions by Samsara BioCapital, L.P., where he holds indirect beneficial ownership.
Summary
- On May 2, 2025, Srinivas Akkaraju, a director of Alumis Inc., indirectly acquired 159,920 shares of common stock at a weighted average price of $4.55, with individual prices ranging from $3.97 to $4.84.
- On May 5, 2025, Akkaraju indirectly acquired 138,368 shares at a weighted average price of $4.58 (ranging from $4.19 to $5.1899) and an additional 22,002 shares at a weighted average price of $5.27 (ranging from $5.19 to $5.48).
- These transactions were executed through Samsara BioCapital, L.P., where Akkaraju, as the managing member of Samsara BioCapital GP, LLC, shares voting and investment authority.
- Following these transactions, Akkaraju's indirect beneficial ownership in Alumis Inc. common stock increased to 3,586,788 shares.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the director's increased investment, suggesting confidence in the company's prospects. However, it's crucial to consider the context and potential motivations behind the purchases.
Positives
- Director Akkaraju's increased investment could signal confidence in Alumis Inc.'s future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that those with the most knowledge of the company believe its stock is undervalued or poised for growth. However, it's important to consider the size of the purchases relative to the insider's existing holdings and the overall market capitalization of the company.
Comparison to Industry Standards
- Comparing Akkaraju's transactions to other insider activity in the biotech sector could provide context.
- For example, if other executives at similar-stage companies are also increasing their holdings, it could signal broader optimism in the industry.
- Conversely, if insider buying is isolated to Alumis Inc., it could be specific to the company's prospects.
Stakeholder Impact
- Shareholders may view the director's increased stake as a positive signal.
- Employees might see it as a sign of stability and confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 05/02/2025 | Purchase of 159,920 shares of common stock at a weighted average price of $4.55. |
| 05/05/2025 | Purchase of 138,368 shares of common stock at a weighted average price of $4.58 and 22,002 shares at a weighted average price of $5.27. |
| 05/06/2025 | Date of signature for the Form 4 filing. |
Keywords
Alumis Inc., Srinivas Akkaraju, Samsara BioCapital, common stock, beneficial ownership, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.